Leading Research That Has Changed HCM
Lahey Hospital & Medical Center cardiologists are responsible for a vast literature that has defined modern HCM diagnosis and treatment. Key papers for your reference and reading include:
- Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Dearani JA, Rowin EJ, Maron MS, Sherrid MV. Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. JACC 2022; 79:390-414.
- Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Rowin EJ, Maron MS, Sherrid MV. Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: State-of-the-Art Review. JACC 2022; 79: 372-89.
- Maron BJ. Clinical Course and Management of Hypertrophic Cardiomyopathy. N Eng J Med, 2018; 379: 655-668.
- Maron BJ, Rowin EJ, Maron MS. Global Burden of Hypertrophic Cardiomyopathy. JACC Heart Fail, 2018; 6:376-8.
- Maron MS. Rowin EJ, Wessler BS, Mooney PJ, Fatima A, Patel P, Koethe BC, Romashko M, Link MS, Maron BJ. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Death in High-Risk Patients with Hypertrophic Cardiomyopathy. JAMA-Cardiol 2019; 4: 644-657.1036.
- Maron BJ, Rowin EJ, Maron MS. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: 20 years with the implantable cardioverter-defibrillator. Heart Rhythm 2021; 18: 1012-1023.
- Maron BJ, Rowin EJ, Casey SA, Lesser JR, Garberich RF, McGriff DM, Maron MS. Hypertrophic Cardiomyopathy in Children, Adolescents and Young Adults Associated with Low Cardiovascular Mortality with Contemporary Management Strategies. Circulation. 2016;133:62-73.
- Maron BJ, Haas TS, Ahluwalia A, Murphy CJ, Garberich RF. Demographics and Epidemiology of Sudden Death in Young Competitive Athletes: From the United States National Registry. Am J Med 2016: 129; 1170-77.
- Rowin EJ, Maron BJ, Haas TS, Garberich RF, Wang W, Link MS, Maron MS. Hypertrophic Cardiomyopathy with Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. JACC. 2017; 69:761-776.
- Rowin EJ, Sridharan A, Madias C, Firely C, Koethe B, Maron MS, Maron BJ. Prediction and Prevention of Sudden Death in Young Patients (<20 years) with Hypertrophic Cardiomyopathy. Am J Cardiol 2020; 128: 75-83.
- Maron MS, Brush J, Rowin EJ, Maron BJ. Back to the Future: Predicting Sudden Death Events in Hypertrophic Cardiomyopathy Relying on Individual Risk Markers and Physician Judgment Without Mathematical Scoring. Heart Rhythm 2021; 18: 148-150.
- Maron MS, Steiger N, Burrows A, Madias C, Weinstock J, Link MS, Rowin EJ, Maron BJ. Evidence that Subcutaneous Implantable Cardioverter-Defibrillators Are Effective and Reliable in Hypertrophic Cardiomyopathy. JACC Clin Electrophysiol 2020; 6: 1019-21.
- Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Ahmed A, Autore C, Boriani G, Winters SL, Giudici M, Koulova A, Garberich R, Rowin, EJ, Sears SF, Maron MS, Spirito P. Clinical Course and Quality of Life in High-Risk Patients with Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators. Circ Cardiovasc Electro, e005820.
- Maron BJ, Rowin EJ, Maron MS. Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy. Circ Res, 2019; 125: 370-8.
- Maron BJ, Rowin EJ, Casey SA, Maron MS. How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease with Low Mortality: Shaped by 50 years of Clinical Research and Practice. JAMA Cardiol 2016; 1:98-105.
- Maron BJ, Rowin EJ, Maron MS. Hypertrophic Cardiomyopathy: Is a “Cure” Coming…or Is It Already Here? Am J Med 2020; 133: 886-888. Erratum 2021; 134: 412.
- Maron BJ, Maron MS, Maurer MS, Rowin EJ, Maron BA, Galie N. Cardiovascular Diseases That Have Emerged from the Darkness. JAHA 2021; 10: e021095.
- Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Dearani JA, Rowin EJ, Maron MS, Sherrid MV. Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. JACC 2022; 79: 390-414.
- Maron BJ, Braunwald E. Evolution of Hypertrophic Cardiomyopathy to a Contemporary Treatable Disease. Circulation 2012; 126:1640-1644.
- Maron MS, Rastegar HR, Dolan N, Carpino P, Koethe B, Maron BJ, Rowin EJ. Outcomes Over Follow-Up ≥ 10 Years After Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy. Am J Cardiol 2022; 163: 91-97.
- Maron BJ, Maron MS, Maron BA, Loscalzo J. Moving Beyond the Sarcomere To Explain Heterogeneity in Hypertrophic Cardiomyopathy. JACC Topic of the Week. 2019; 73: 1978-1986.
- Maron BA, Wang R-S, Shevtsov S, Drakos SG, Arons E, Wever-Pinzon OW, Huggins GS, Samokhin AO, Oldham WM, Aquib Y, Yacoub MH, Rowin EJ, Maron BJ, Maron MS, Loscalzo J. Network-Based Precision Medicine in Complex Phenotypes: Individualized Interactomes in Hypertrophic Cardiomyopathy and Their Clinical Implications. Nat Commun 2021; 12: 873.
- Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, Rastegar H, Estes NAM, Maron MS, Maron BJ. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation, 2017; 136:2420-2436.
- Rowin EJ, Orfanos A, Estes NAM, Wang W, Link MS, Maron MS, Maron BJ. Occurrence and Natural History of Clinically Silent Episodes of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Am J Cardiol, 2017; 119:1862-65.